Biggest News Aggregation in the World
📰 Acerta Astrazeneca News

Acerta Astrazeneca News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Acerta Astrazeneca. Real-time updates on events, politics, business and more.

Zanubrutinib prolongs PFS with fewer cardiac events vs. ibrutinib in advanced CLL, SLL

NEW ORLEANS — Zanubrutinib significantly prolonged PFS compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, results of the phase 3 ALPINE study showed.The second-generation Bruton tyrosine kinase (BTK) inhibitor also had a better safety profile than ibrutinib (Imbruvica; Pharmacyclics, Janssen), particularly with
Margaret Collette Sun Pharma Jenniferr Brown Bristol Myers Squibb Mindy Valcarcel Acerta Astrazeneca
Source: healio.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science